Q-omics provides the consensus-scored SRD5A3P1 profile across patient tissues and cancer cell-line models. SRD5A3P1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SRD5A3P1 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, SRD5A3P1 RNA expression shows 5,142 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight UCS, LUAD, and UCEC as cancer lineages where SRD5A3P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRD5A3P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRD5A3P1 survival associations across molecular data types. SRD5A3P1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRD5A3P1 RNA expression–survival associations across cancer types. High SRD5A3P1 expression shows unfavorable associations in UCS, LIHC, KICH, MESO and BLCA, but favorable associations in ESCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .022). Together, the overview and detailed table identify UCS as the clearest survival context for SRD5A3P1 RNA expression.
This table summarizes SRD5A3P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SRD5A3P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRD5A3P1 shows lower tumor expression in READ and higher tumor expression in LUAD, BRCA and KIRC. The LUAD box plot shows higher SRD5A3P1 RNA expression in tumor versus normal tissue (log2 FC = +0.032, t-test p = .004).
This table shows molecular features associated with SRD5A3P1 in patient tissues and cancer cell lines. In patient samples, SRD5A3P1 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
